Vertex Pharmaceuticals Incorporated (LON:0QZU)
490.24
+0.10 (0.02%)
At close: Apr 17, 2025
Vertex Pharmaceuticals Revenue
In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B USD with 11.66% growth. Vertex Pharmaceuticals had revenue of $2.91B in the quarter ending December 31, 2024, with 15.66% growth.
Revenue
$11.02B
Revenue Growth
+11.66%
P/S Ratio
10.83
Revenue / Employee
$1.81M
Employees
6,100
Market Cap
95.31B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Vertex Pharmaceuticals News
- 11 days ago - Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF Research - GuruFocus
- 12 days ago - CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades' - Benzinga
- 13 days ago - Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis - Business Wire
- 13 days ago - Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? - The Motley Fool
- 13 days ago - GreensKeeper Q1 2025 Portfolio Update - Seeking Alpha
- 15 days ago - Is Vertex Pharmaceuticals Stock a Buy? - The Motley Fool
- 16 days ago - European Commission Expands Approval for Vertex's Kaftrio (VRTX) - GuruFocus
- 16 days ago - Vertex to Announce First Quarter 2025 Financial Results on May 5th - Business Wire